Top
image credit: Unsplash

Roche rings Bicycle bell again, grabbing another cancer target

July 13, 2022

Category:

Bicycle’s bicyclic peptide drug discovery platform is designed to produce drug candidates that have targeting properties like antibodies but are much smaller molecules, making manufacturing and dosing easier.

The time the peptides stay in the body can also be fine-tuned, allowing for precise control of drug exposure, according to the biotech.

Genentech has been looking at the platform since 2020 under the terms of a deal worth up to $1.7 billion that give it opt-in rights to two immuno-oncology targets, plus scope to extend the alliance with two more in return for a $10 million fee apiece.

Read More on Pharmaphorum